In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS


IQ-SPECT multifocal collimator myocardial perfusion imaging in clinical practice

Session Moderated Posters 4

Speaker Amelia Jimenez-Heffernan

Congress : ICNC, Nuclear Cardiology & Cardiac CT 2019

  • Topic : imaging
  • Sub-topic : Single Photon Emission Computed Tomography (SPECT)
  • Session type : Moderated Posters
  • FP Number : 238

Authors : A Jimenez-Heffernan (Huelva,ES), E Sanchez De Mora (Huelva,ES), J Lopez-Martin (Huelva,ES), T Aroui (Huelva,ES), C Salgado (Huelva,ES), M Molina (Huelva,ES), R Lopez-Aguilar (Huelva,ES), G Isasti (Huelva,ES)

A Jimenez-Heffernan1 , E Sanchez De Mora1 , J Lopez-Martin1 , T Aroui1 , C Salgado1 , M Molina1 , R Lopez-Aguilar2 , G Isasti2 , 1Hospital Juan Ramon Jimenez, Nuclear Medicine - Huelva - Spain , 2Hospital Juan Ramon Jimenez, Cardiology - Huelva - Spain ,


High image quality with short acquisition times and/or radiation reduction is possible with new cardiac dedicated solid-state cameras but these are not widely available. Smartzoom multifocal cardio-focused collimation allows half and quarter acquisition times with high quality images using conventional NaI camera SPECT.
We aim to assess the performance of IQ SPECT MPI in every day clinical practice.
We studied 492 consecutive patients (57.3% female, age: 68.2 ± 10.6 years, BMI: 29.8 ± 4.8) for diagnosis or prognostic assessment of coronary artery disease with IQ SPECT MPI on a Symbia Intevo 6 camera using 99mTc-tracers at standard doses. Acquisition parameters were 208º scan arc, 6 angular steps, 17 views/detector, 9 seconds/view, angle between detectors set at 76º and matrix 1282 with a total acquisition time of 5 minutes. Reconstruction included resolution recovery, CT-based attenuation correction (AC) and energy window-based scatter correction. Stress was low-level exercise combined with regadenoson in 356 and adenosine in 136 and patients respectively. Normalcy rate using a low pretest likelihood of disease and LVEF quantification were obtained and compared to that of 461 previous patients (52% male, age: 64.6 ± 11.7 years, BMI: 30.2 ± 7.3) who underwent SPECT using a standard hybrid camera (180º arc, 30 views/detector, 12 seconds/view, 90º angle and matrix 1282) with OSEM-RR reconstruction with CT-AC and total acquisition time 12 minutes, all other procedure parameters identical.  One-year cardiac event rate was obtained from the 327 patients with at least one year of follow-up.
Images were of good quality and showed the typical hot apex on uncorrected images and slight apical thinning on CT-AC images. MPI was reported as normal in 44.3%, abnormal in 54.5% and equivocal in 1.2% of patients respectively. Normalcy rate was 61%. In the standard camera group reports were normal in 46.7%, abnormal in 51.3% and equivocal in 2% of patients respectively and the normalcy rate was 57.8%. Mean post-stress LVEF in normal perfusion patients was 64.7% ± 9.5 vs 63.3% ± 11 for the standard SPECT group. In patients with normal perfusion, at one year there were no deaths but one diagonal branch revascularization in a female patient.  
IQ SPECT produces ultrafast images of good quality with a characteristic apex pattern to be learned for correct reporting, not to be mistaken on uncorrected images with the "solar map" of apical hypertrophic cardiomyopathy.

This content is currently on FREE ACCESS


Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are